Jubilant Ingrevia Acquires Remidex Pharma for Rs 16.5 Cr

Jubilant Ingrevia Limited signed a Share Purchase Agreement on March 13, 2026, to acquire 100% equity stake in Remidex Pharma Private Limited for Rs 16.5 crore cash consideration, making it a wholly owned subsidiary.

Target Company Profile

Bangalore-based Remidex, incorporated June 15, 1981, manufactures micronutrient premixes, nutraceuticals, and serves as contract manufacturer for Indian/multinational pharma firms. FY25 turnover Rs 24.27 crore (FY24: Rs 31.15 crore; FY23: Rs 30.51 crore) with WHO-GMP, FSSC, FSSAI certified facility.

Strategic Expansion

The non-related party acquisition advances Jubilant Ingrevia up the human nutrition value chain from vitamins (B3, B4) leadership into premixes, targeting completion within 30 days.

Shares of Jubilant Ingrevia Limited was last trading in BSE at Rs. 559.10 as compared to the previous close of Rs. 577.90. The total number of shares traded during the day was 6144 in over 692 trades.

The stock hit an intraday high of Rs. 576.00 and intraday low of 548.15. The net turnover during the day was Rs. 3439931.00.

Source : Equity Bulls

Keywords

JubilantIngrevia INE0BY001018 SpecialtyChemicals Acquisition RemidexPharma